Skip to main content

Drug Interactions between anagrelide and FemSeven Sequi Phase I

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

estradiol anagrelide

Applies to: FemSeven Sequi Phase I (estradiol) and anagrelide

Consumer information for this interaction is not currently available.

MONITOR: Theoretically, coadministration with drugs that are inhibitors of CYP450 1A2 may increase the plasma concentrations of anagrelide, which is a substrate of the isoenzyme.

MANAGEMENT: Clinicians should recognize the potential for interaction with drugs that inhibit CYP450 1A2 and monitor for evidence of anagrelide toxicities during coadministration. Since platelet reduction from anagrelide therapy is dose-related, thrombocytopenia may occur due to reduced clearance of anagrelide and may be a sign of overdosage. Patients should also be monitored for cardiovascular adverse effects such as tachycardia, palpitations, hypotension, edema, and congestive heart failure.

Drug and food interactions

Minor

estradiol food

Applies to: FemSeven Sequi Phase I (estradiol)

Information for this minor interaction is available on the professional version.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer